Propafenone analogue with additional H-bond acceptor group shows increased inhibitory activity on P-glycoprotein
- PMID: 31917466
- DOI: 10.1002/ardp.201900269
Propafenone analogue with additional H-bond acceptor group shows increased inhibitory activity on P-glycoprotein
Abstract
P-glycoprotein (P-gp) is an ATP-dependent efflux pump that has a marked impact on the absorption, distribution, and excretion of therapeutic drugs. As P-gp inhibition can result in drug-drug interactions and altered drug bioavailability, identifying molecular properties that are linked to inhibition is of great interest in drug development. In this study, we combined chemical synthesis, in vitro testing, quantitative structure-activity relationship analysis, and docking studies to investigate the role of hydrogen bond (H-bond) donor/acceptor properties in transporter-ligand interaction. In a previous work, it has been shown that propafenone analogs with a 4-hydroxy-4-piperidine moiety exhibit a generally 10-fold higher P-gp inhibitory activity than expected based on their lipophilicity. Here, we specifically expanded the data set by introducing substituents at position 4 of the 4-phenylpiperidine moiety to assess the importance of H-bond donor/acceptor features in this region. The results suggest that indeed an H-bond acceptor, such as hydroxy and methoxy, increases the affinity by forming a H-bond with Tyr310.
Keywords: P-glycoprotein; inhibitor; molecular docking; propafenone; quantitative structure-activity relationship.
© 2020 The Authors. Archiv der Pharmazie published by Wiley-VCH Verlag GmbH & Co. KGaA on behalf of Deutsche Pharmazeutische Gesellschaft.
Similar articles
-
Intramolecular distribution of hydrophobicity influences pharmacological activity of propafenone-type MDR modulators.Arch Pharm (Weinheim). 2004 Jun;337(6):328-34. doi: 10.1002/ardp.200300862. Arch Pharm (Weinheim). 2004. PMID: 15188222
-
Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.J Med Chem. 2012 Apr 12;55(7):3261-73. doi: 10.1021/jm201705f. Epub 2012 Mar 27. J Med Chem. 2012. PMID: 22452412 Free PMC article.
-
Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements.Biochem Pharmacol. 1999 Nov 1;58(9):1447-56. doi: 10.1016/s0006-2952(99)00229-4. Biochem Pharmacol. 1999. PMID: 10513988
-
P-glycoprotein recognition of substrates and circumvention through rational drug design.Mol Pharm. 2006 Jan-Feb;3(1):3-25. doi: 10.1021/mp0500871. Mol Pharm. 2006. PMID: 16686365 Review.
-
Recent advances in the development of P-gp inhibitors.Anticancer Agents Med Chem. 2009 May;9(4):415-36. doi: 10.2174/1871520610909040415. Anticancer Agents Med Chem. 2009. PMID: 19442042 Review.
Cited by
-
Antifungal activity of compounds from Gordonia sp. WA8-44 isolated from the gut of Periplaneta americana and molecular docking studies.Heliyon. 2023 Jul 4;9(7):e17777. doi: 10.1016/j.heliyon.2023.e17777. eCollection 2023 Jul. Heliyon. 2023. PMID: 37539250 Free PMC article.
References
REFERENCES
-
- E. E. Chufan, H.-M. Sim, S. V. Ambudkar ABC Transporters and Cancer, Vol. 125 (Eds: J. D. Schuetz, T. Ishikawa), Academic Press, New York, NY 2015, Ch. 3.
-
- F. J. Sharom, Essays Biochem. 2011, 50, 161. https://doi.org/10.1042/bse0500161
-
- R. Silva, V. Vilas-Boas, H. Carmo, R. J. Dinis-Oliveira, F. Carvalho, M. de Lourdes Bastos, F. Remião, Pharmacol. Ther. 2015, 149, 1. https://doi.org/10.1016/j.pharmthera.2014.11.013
-
- J. König, F. Müller, M. F. Fromm, Pharmacol. Rev. 2013, 65, 944. https://doi.org/10.1124/pr.113.007518
-
- Z. Chen, T. Shi, L. Zhang, P. Zhu, M. Deng, C. Huang, T. Hu, L. Jiang, Cancer Lett. 2016, 370, 153. https://doi.org/10.1016/j.canlet.2015.10.010
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
